Effectiveness of Vericiguat on right ventricle to pulmonary artery uncoupling associated with heart failure with reduced ejection fraction.
Toru HashimotoTomoaki YoshitakeTomoyasu SuenagaShoei YamamotoTakeo FujinoKeisuke ShinoharaShouji MatsushimaTomomi IdeShintaro KinugawaKohtaro AbePublished in: International journal of cardiology (2024)
Treatment with vericiguat improved adverse LV remodeling and RV-PA uncoupling in HFrEF patients. These effects were independent of WHF and achieving the quadruple therapy. Patients with HFrEF may benefit from early initiation of vericiguat to prevent biventricular adverse remodeling.
Keyphrases
- pulmonary artery
- pulmonary hypertension
- coronary artery
- heart failure
- pulmonary arterial hypertension
- end stage renal disease
- ejection fraction
- randomized controlled trial
- chronic kidney disease
- mycobacterium tuberculosis
- helicobacter pylori
- systematic review
- prognostic factors
- left ventricular
- cardiac resynchronization therapy
- nitric oxide synthase
- stem cells
- adverse drug
- acute heart failure
- congenital heart disease
- patient reported
- smoking cessation